PSA Test: What a Raised PSA Does and Does Not Mean

Your PSA came back higher than expected, and the word "cancer" may be the first thing on your mind. Take a breath. Most men with a raised PSA do not have prostate cancer. This guide explains what PSA is, what can raise it, how clinicians decide what to do next, and how Canadian and US screening advice differs.

What PSA is

Prostate-specific antigen (PSA) is a protein made by the prostate, a small gland below the bladder in men. A small amount enters the blood. The PSA test measures that amount, usually in ng/mL. Canadian labs may report µg/L, which is the same number [1][6].

PSA rises with prostate cancer. But it also rises with many common, non-cancer conditions. That is why PSA is a signal to look further, not a diagnosis.

Common non-cancer causes of a raised PSA

• Benign prostatic hyperplasia (BPH): an enlarged prostate, which is very common with age.
• Prostatitis: inflammation or infection of the prostate.
• Urinary tract infection.
• Recent ejaculation.
• Long bike rides.
• Recent procedures, such as a catheter or cystoscopy.
• Older age, since PSA naturally rises over time [1].

Some medicines, such as finasteride and dutasteride, lower PSA by about half. Clinicians adjust how they read the result if you take them [1].

What your doctor looks at

The number and the trend

A PSA of 4.0 ng/mL is a common cut point for "abnormal." Some clinicians use a lower cut point, such as 2.5, for younger men and a higher one for older men [1]. Clinicians also look at:

• How fast PSA is rising over time.
• PSA density: the PSA divided by the size of the prostate. Higher density raises concern.
• Your age, family history, and ancestry. Black men and men with a father or brother who had prostate cancer have a higher risk.

Repeat first

Because PSA changes with infection, ejaculation, and other factors, a raised result is often repeated in a few weeks. A urine test may check for infection. Many raised results come back lower on repeat.

Biopsy is not automatic

Only about 25 percent of men who have a biopsy because of a raised PSA are found to have prostate cancer [1]. Today, many clinicians use an MRI of the prostate before deciding on a biopsy. A normal MRI can help some men avoid a biopsy. Risk calculators and other blood or urine tests may also help.

Not all prostate cancers need treatment

Many prostate cancers found through PSA testing grow slowly and would never cause harm. This is called overdiagnosis. For low-risk cancers, many men choose active surveillance: regular PSA tests, MRI, and sometimes repeat biopsies instead of surgery or radiation right away.

The screening debate

Screening means testing men without symptoms. This is where Canadian and US guidance differ.

US: an individual choice

The US Preventive Services Task Force (USPSTF) 2018 recommendation says that for men aged 55 to 69, PSA screening should be an individual decision made with a clinician (grade C). It recommends against PSA screening for men 70 and older (grade D) [2]. It notes a small chance of benefit and real chances of harm, including false positives, biopsies, overdiagnosis, and treatment side effects such as incontinence and erectile problems.

Canada: against routine screening

The Canadian Task Force on Preventive Health Care 2014 guideline recommends not screening with PSA at any age. For men aged 55 to 69 this was a weak recommendation [3]. The Task Force ended its mandate in March 2026, and its guideline remains posted for reference. Some Canadian specialist groups, such as the Canadian Urological Association, support offering PSA testing after a shared decision. In practice, many Canadian clinicians discuss PSA testing with men who ask.

What newer evidence shows

The European screening trial (ERSPC) followed about 162,000 men aged 55 to 69 for a median of 23 years. Prostate cancer deaths were 13 percent lower in the group invited to screening. In absolute terms, about 1 prostate cancer death was prevented for every 456 men invited [4]. More men in the screened group were diagnosed with prostate cancer. A 2026 Cochrane review concluded that screening likely reduces deaths from prostate cancer, but that evidence on harms is limited [5].

These results may shape future guidance. For now, the decision is personal and depends on your values and risk.

Questions to ask your clinician

• What is my PSA, and how has it changed over time?
• Could an infection, an enlarged prostate, or a medicine explain it?
• Should we repeat the test before anything else?
• Would an MRI help decide if I need a biopsy?
• What is my personal risk, based on age, family history, and ancestry?
• If cancer is found, would active surveillance be an option?
• What are the benefits and harms of screening for someone like me?

When to get care quickly

Go to the emergency department if you:

• Cannot pass urine at all, or have severe pain in your lower belly.
• Have fever, chills, and pain when passing urine or in the area between your legs.
• See large amounts of blood or clots in your urine.
• Have new back pain with leg weakness, numbness, or loss of bladder or bowel control. Call 911.

Bottom line

A raised PSA is common and usually not cancer. Clinicians repeat the test, look for other causes, and often use MRI before a biopsy. Screening is a personal choice in the US for men 55 to 69, and Canada's task force advised against routine screening. Long-term data show a small benefit, so a clear talk about your own risks and values matters most.

Primary AI can show you the guideline and study sources behind this topic in plain language, so you can bring better questions to your appointment.